News UEGW delegates hear of strides forward in IBD treatment Trials of Lilly's Omvoh, Gilead's emvistegrast, Takeda's Entyvio, AbbVie's ABBV-466, and Sanofi/Teva's duvakitug are highlights of UEGW.
News MSD taps Quotient for IBD drug targets in $2.2bn deal MSD is paying $20m upfront to activate an alliance with Flagship's Quotient Therapeutics to find new targets in inflammatory bowel disease.
News Earendil raises $787m as lead TL1A antibody starts phase 2 Earendil has raised an impressive $787m in financing for its AI-powered drug platform, attracting yet more buy-in from Sanofi.
News Boehringer signs €1bn+ deal for Simcere IBD candidate Boehringer Ingelheim has sourced an IL-23p19xTL1A bispecific antibody for inflammatory bowel disease, from China's Simcere, for €42m upfront.
News Abivax climbs on Lilly takeover speculation Shares in Abivax were tracking up this morning as a media report in France suggested it could see a €15bn takeover offer from Eli Lilly.
News NICE backs new drugs for Crohn's disease, lymphoma Eli Lilly's Omvoh has been recommended for use in Crohn's disease by NICE, while BeOne's Brukinsa gets the go-ahead for mantle cell lymphoma.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.